Oncotype DX and Prosigna in breast cancer patients: A comparison study

DeSantis, 2019, Breast cancer statistics, 2019, CA. Cancer J. Clin., 69, 438, 10.3322/caac.21583 Mansour, 1989, Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer, N. Engl. J. Med., 10.1056/NEJM198902233200803 Fisher, 1997, Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor- positive breast cancer, J. Natl. Cancer Inst., 10.1093/jnci/89.22.1673 Abrams, 2001, Adjuvant therapy for breast cancer - results from the USA consensus conference, Breast Cancer, 10.1007/BF02967528 Sparano, 2008, Development of the 21-gene assay and its application in clinical practice and clinical trials, J. Clin. Oncol., 10.1200/JCO.2007.15.1068 Paik, 2004, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N. Engl. J. Med., 10.1056/NEJMoa041588 Cardoso, 2008, Clinical application of the 70-gene profile: the MINDACT trial, J. Clin. Oncol., 10.1200/JCO.2007.14.3222 Arpino, 2013, Gene expression profiling in breast cancer: a clinical perspective, Breast, 10.1016/j.breast.2013.01.016 Paik, 2006, Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer, J. Clin. Oncol., 10.1200/JCO.2005.04.7985 Albain, 2010, Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial, Lancet Oncol, 10.1016/S1470-2045(09)70314-6 Sparano, 2020, Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial, JAMA Oncol, 10.1001/jamaoncol.2019.4794 Sparano, 2018, Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer, N. Engl. J. Med., 10.1056/NEJMoa1804710 Geiss, 2008, Direct multiplexed measurement of gene expression with color-coded probe pairs, Nat. Biotechnol. Nielsen, 2010, A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer, Clin. Cancer Res., 10.1158/1078-0432.CCR-10-1282 Perou, 2000, Molecular portraits of human breast tumours, Nature, 10.1038/35021093 Bastien, 2011, Using the PAM50 breast cancer intrinsic classifier to assess risk in ER+ breast cancers: a direct comparison to Onco type DX, J. Clin. Oncol., 10.1200/jco.2011.29.15_suppl.503 Bernard, 2009, Supervised risk predictor of breast cancer based on intrinsic subtypes, J. Clin. Oncol. Dowsett, 2013, Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy, J. Clin. Oncol., 10.1200/JCO.2012.46.1558 Gnant, 2012 Gnant, 2013, Predicting risk for late metastasis: the PAM50 risk of recurrence (ROR) score after 5 years of endocrine therapy in postmenopausal women with Hr+ early breast cancer: a study on 1,478 patients from the Abcsg-8 Trial, Ann. Oncol., 10.1093/annonc/mdt084.1 Gnant, 2014, Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone, Ann. Oncol., 10.1093/annonc/mdt494 Alvarado, 2015, A prospective comparison of the 21-gene Recurrence Score and the PAM50-based prosigna in estrogen receptor-positive early-stage breast cancer, Adv. Ther., 10.1007/s12325-015-0269-2 Toi, 2010, Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population, Cancer, 10.1002/cncr.25206 Stein, 2016, OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer, Health Technol. Assess. (Rockv)., 10.3310/hta20100 Clough, 2012, Abstract P6-07-03: risk classification of early stage breast cancer as assessed by MammaPrint and Oncotype DX genomic assays, Cancer Res, 72, 10.1158/0008-5472.SABCS12-P6-07-03 Shivers, 2013 Mook, 2009, The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study, Breast Cancer Res. Treat., 10.1007/s10549-008-0130-2 Bueno-de-Mesquita, 2007, Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER), Lancet Oncol, 10.1016/S1470-2045(07)70346-7 Filipits, 2011, A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors, Clin. Cancer Res., 10.1158/1078-0432.CCR-11-0926 Fitzal, 2015, The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial, Br. J. Cancer., 10.1038/bjc.2015.98 Varga, 2019, Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer, Int. J. Cancer., 10.1002/ijc.32139 Albanell, 2016, Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor–positive, human epidermal growth factor receptor 2–negative early-stage breast ca, Eur. J. Cancer., 10.1016/j.ejca.2016.06.027 Buus, 2016, Comparison of endopredict and epclin with oncotype dx recurrence score for prediction of risk of distant recurrence after endocrine therapy, J. Natl. Cancer Inst., 10.1093/jnci/djw149 Klein, 2013, Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis, Mod. Pathol., 10.1038/modpathol.2013.36 Braunstein, 2016, Molecular phenotype, multigene assays, and the locoregional management of breast cancer, Semin. Radiat. Oncol., 10.1016/j.semradonc.2015.08.002 Tan, 2018, Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer, Asia. Pac. J. Clin. Oncol., 14, e161, 10.1111/ajco.12779